These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 25560051)

  • 21. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
    Srinivas NR
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
    Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
    Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
    J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
    Pedersen RS; Damkier P; Brøsen K
    Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs.
    KuKanich B; Papich MG
    J Vet Pharmacol Ther; 2004 Aug; 27(4):239-46. PubMed ID: 15305853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
    Madani S; Barilla D; Cramer J; Wang Y; Paul C
    J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.
    Ahonen J; Olkkola KT; Neuvonen PJ
    Br J Clin Pharmacol; 1995 Sep; 40(3):270-2. PubMed ID: 8527290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
    Halling J; Weihe P; Brosen K
    Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers.
    de Moraes NV; Lauretti GR; Lanchote VL
    J Pharm Pharmacol; 2014 Sep; 66(9):1222-30. PubMed ID: 24717054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The hypoalgesic effect of tramadol in relation to CYP2D6.
    Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH
    Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in Tramadol: Pharmacology, Metabolism, and Misuse.
    Miotto K; Cho AK; Khalil MA; Blanco K; Sasaki JD; Rawson R
    Anesth Analg; 2017 Jan; 124(1):44-51. PubMed ID: 27861439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
    Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
    Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
    de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
    Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.
    Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F
    Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
    Gan SH; Ismail R; Wan Adnan WA; Zulmi W
    Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of oral tramadol pharmacokinetics in horses.
    Cox S; Villarino N; Doherty T
    Res Vet Sci; 2010 Oct; 89(2):236-41. PubMed ID: 20223494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats.
    Sheikholeslami B; Gholami M; Lavasani H; Rouini M
    Eur J Pharm Sci; 2016 Sep; 92():55-63. PubMed ID: 27365222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.